Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

Eva Stadler^#¹, Mohamed Maiga^#², Lukas Friedrich^#³, Vandana Thathy^#^{4

5}, Claudia Demarta-Gatsi⁶, Antoine Dara², Fanta Sogore², Josefine Striepen^{4

7}, Claude Oeuvray⁶, Abdoulaye A Djimdé², Marcus C S Lee^{8

9}, Laurent Dembélé¹⁰, David A Fidock^{11

12

13}, David S Khoury¹⁴, Thomas Spangenberg¹⁵

Affiliations

¹ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
² Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.
³ Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, 64293, Darmstadt, Germany.
⁴ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
⁵ Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA.
⁶ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland.
⁷ Weill Cornell Medical College, New York, NY, 10021, USA.
⁸ Wellcome Sanger Institute, Wellcome Genome Campus, CB10 1SA, Hinxton, UK.
⁹ Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, DD1 4HN, Scotland, UK.
¹⁰ Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali. laurent@icermali.org.
¹¹ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹² Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹³ Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹⁴ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia. dkhoury@kirby.unsw.edu.au.
¹⁵ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland. thomas.spangenberg@merckgroup.com.

^# Contributed equally.

PMID: 37673924
PMCID: PMC10482846
DOI: 10.1038/s41467-023-41287-6

Published Erratum

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

Eva Stadler et al. Nat Commun. 2023.

. 2023 Sep 6;14(1):5447.

doi: 10.1038/s41467-023-41287-6.

Authors

Affiliations

¹ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
² Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.
³ Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, 64293, Darmstadt, Germany.
⁴ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
⁵ Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA.
⁶ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland.
⁷ Weill Cornell Medical College, New York, NY, 10021, USA.
⁸ Wellcome Sanger Institute, Wellcome Genome Campus, CB10 1SA, Hinxton, UK.
⁹ Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, DD1 4HN, Scotland, UK.
¹⁰ Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali. laurent@icermali.org.
¹¹ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹² Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹³ Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.
¹⁴ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia. dkhoury@kirby.unsw.edu.au.
¹⁵ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland. thomas.spangenberg@merckgroup.com.

^# Contributed equally.

PMID: 37673924
PMCID: PMC10482846
DOI: 10.1038/s41467-023-41287-6

No abstract available

PubMed Disclaimer

Erratum for

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine.
Stadler E, Maiga M, Friedrich L, Thathy V, Demarta-Gatsi C, Dara A, Sogore F, Striepen J, Oeuvray C, Djimdé AA, Lee MCS, Dembélé L, Fidock DA, Khoury DS, Spangenberg T. Stadler E, et al. Nat Commun. 2023 Aug 25;14(1):5205. doi: 10.1038/s41467-023-40974-8. Nat Commun. 2023. PMID: 37626093 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

Affiliations

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources